Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

2.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May 16. doi: 10.1038/s41416-018-0087-9. [Epub ahead of print]

PMID:
29765151
3.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
4.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
5.

TRAF molecules in inflammation and inflammatory diseases.

Lalani AI, Zhu S, Gokhale S, Jin J, Xie P.

Curr Pharmacol Rep. 2018 Feb;4(1):64-90. doi: 10.1007/s40495-017-0117-y. Epub 2017 Dec 20.

PMID:
29527458
6.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

7.

Assessment of orthodontic treatment need among tribal children of Indore division, Central India.

Muralidharan S, Chauhan A, Gowda S, Ambekar R, Rathore BS, Chabra S, Lalani A, Harani H.

Clujul Med. 2018;91(1):104-111. doi: 10.15386/cjmed-795. Epub 2018 Jan 15.

8.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
9.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

PMID:
29420467
10.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

PMID:
29405820
11.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

12.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
13.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

14.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

15.

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK.

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. No abstract available.

PMID:
29217289
16.

Immunotherapy in the Elderly.

Lalani AA, Bossé D, McGregor BA, Choueiri TK.

Eur Urol Focus. 2017 Oct;3(4-5):403-412. doi: 10.1016/j.euf.2017.11.008. Epub 2017 Nov 26. Review.

PMID:
29183736
17.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27.

18.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.

PMID:
28864222
19.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

20.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

21.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

PMID:
28679771
22.

Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):724-732. doi: 10.1016/j.clgc.2017.05.019. Epub 2017 May 31.

PMID:
28645482
23.

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.

24.

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8.

25.

Regulation of Physical Microglia-Neuron Interactions by Fractalkine Signaling after Status Epilepticus.

Eyo UB, Peng J, Murugan M, Mo M, Lalani A, Xie P, Xu P, Margolis DJ, Wu LJ.

eNeuro. 2017 Jan 16;3(6). pii: ENEURO.0209-16.2016. doi: 10.1523/ENEURO.0209-16.2016. eCollection 2016 Nov-Dec.

26.

Management of Patients with Gastroschisis Requiring Extracorporeal Membrane Oxygenation for Concurrent Respiratory Failure.

Lalani A, Benson Ham P 3rd, Wise LJ, Daniel JM 4th, Walters KC, Pipkin WL, Stansfield B, Hatley RM, Bhatia J.

Am Surg. 2016 Sep;82(9):768-72.

PMID:
27670556
27.

Knowledge,attitude and anxiety towards pandemic flu a potential bio weapon among health professionals in Indore City.

Mishra P, Bhadauria US, Dasar PL, N S, Kumar S, Lalani A, Sarkar P, Chauhan A, Godha S, Vyas S.

Przegl Epidemiol. 2016;70(1):41-5, 125-7. English, Polish.

28.

Assessment of relationship between oral health behavior, oral hygiene and gingival status of dental students.

Lalani A, Dasar PL, Sandesh N, Mishra P, Kumar S, Balsaraf S.

Indian J Dent Res. 2015 Nov-Dec;26(6):592-7. doi: 10.4103/0970-9290.176922.

29.

TRAF3: a novel tumor suppressor gene in macrophages.

Lalani AI, Luo C, Han Y, Xie P.

Macrophage (Houst). 2015 Sep 30;2:e1009.

30.

Impact of Dental Neglect Scale on Oral Health Status Among Different Professionals in Indore City-A Cross- Sectional Study.

Sarkar P, Dasar P, Nagarajappa S, Mishra P, Kumar S, Balsaraf S, Lalani A, Chauhan A.

J Clin Diagn Res. 2015 Oct;9(10):ZC67-70. doi: 10.7860/JCDR/2015/14321.6674. Epub 2015 Oct 1.

31.

Functional Outcomes and Health-Related Quality of Life After Surgical Repair of Full-Thickness Rotator Cuff Tears Using a Mini-Open Technique: A Concise 10-Year Follow-up of a Previous Report.

Saraswat MK, Styles-Tripp F, Beaupre LA, Luciak-Corea C, Otto D, Lalani A, Balyk RA.

Am J Sports Med. 2015 Nov;43(11):2794-9. doi: 10.1177/0363546515602017. Epub 2015 Sep 22.

PMID:
26394889
32.

Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.

Lalani AI, Moore CR, Luo C, Kreider BZ, Liu Y, Morse HC 3rd, Xie P.

J Immunol. 2015 Jan 1;194(1):334-48. doi: 10.4049/jimmunol.1401548. Epub 2014 Nov 24.

33.

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.

Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R.

PLoS One. 2014 Nov 13;9(11):e112371. doi: 10.1371/journal.pone.0112371. eCollection 2014.

34.

Manifestations of Von Hippel Lindau syndrome: a retrospective national review.

O' Brien FJ, Danapal M, Jairam S, Lalani AK, Cunningham J, Morrin M, McNally S, Donovan MG, Little D, Tuthill A, Conlon PJ.

QJM. 2014 Apr;107(4):291-6. doi: 10.1093/qjmed/hct249. Epub 2013 Dec 17.

PMID:
24352051
35.

Improved survival associated with pre-hospital triage strategy in a large regional ST-segment elevation myocardial infarction program.

Chan AW, Kornder J, Elliott H, Brown RI, Dorval JF, Charania J, Zhang R, Ding L, Lalani A, Kuritzky RA, Simkus GJ.

JACC Cardiovasc Interv. 2012 Dec;5(12):1239-46. doi: 10.1016/j.jcin.2012.07.013.

36.

Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G.

Cancer Res. 2013 Jan 1;73(1):108-18. doi: 10.1158/0008-5472.CAN-12-2064. Epub 2012 Nov 13.

37.

Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.

Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D.

Gynecol Oncol. 2012 Dec;127(3):579-86. doi: 10.1016/j.ygyno.2012.09.016. Epub 2012 Sep 23.

38.

Coronary anomalies: left main coronary artery aneurysm.

Varda R, Chitimilla SK, Lalani A.

Case Rep Cardiol. 2012;2012:954951. doi: 10.1155/2012/954951. Epub 2012 Aug 5.

39.

In-hospital outcomes of a regional ST-segment elevation myocardial infarction acute transfer and repatriation program.

Chan AW, Bakar SN, Brown RI, Kuritzky R, Lalani A, Gordon W, Laberge CG, Simkus GJ.

Can J Cardiol. 2011 Sep-Oct;27(5):664.e1-8. doi: 10.1016/j.cjca.2010.12.050. Epub 2011 Jul 31.

PMID:
21803534
40.
41.

Predictors of major intervention in infants with bronchiolitis.

Parker MJ, Allen U, Stephens D, Lalani A, Schuh S.

Pediatr Pulmonol. 2009 Apr;44(4):358-63. doi: 10.1002/ppul.21010.

PMID:
19283838
42.

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

Trédan O, Garbens AB, Lalani AS, Tannock IF.

Cancer Res. 2009 Feb 1;69(3):940-7. doi: 10.1158/0008-5472.CAN-08-0676. Epub 2009 Jan 27.

43.

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, Milián ML, Mani S, Tolcher A, Lalani AS, Sarantopoulos J.

Clin Cancer Res. 2008 Nov 1;14(21):7110-5. doi: 10.1158/1078-0432.CCR-08-0483.

44.

A single versus multiple doses of dexamethasone in infants wheezing for the first time.

Schuh S, Coates AL, Dick P, Stephens D, Lalani A, Nicota E, Mokanski M, Khaikin S, Allen U.

Pediatr Pulmonol. 2008 Sep;43(9):844-50. doi: 10.1002/ppul.20845.

PMID:
18668692
45.

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators.

Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461.

46.

Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.

Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ.

Clin Cancer Res. 2008 Feb 15;14(4):1096-104. doi: 10.1158/1078-0432.CCR-07-4020.

47.

Wrist buckle fractures: a survey of current practice patterns and attitudes toward immobilization.

Plint A, Clifford T, Perry J, Bulloch B, Pusic M, Lalani A, Ali S, Nguyen BH, Joubert G, Millar K.

CJEM. 2003 Mar;5(2):95-100.

PMID:
17475098
48.

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD.

Clin Cancer Res. 2007 Apr 1;13(7):2216-25.

49.

Evaluation of the utility of radiography in acute bronchiolitis.

Schuh S, Lalani A, Allen U, Manson D, Babyn P, Stephens D, MacPhee S, Mokanski M, Khaikin S, Dick P.

J Pediatr. 2007 Apr;150(4):429-33.

PMID:
17382126
50.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

Supplemental Content

Loading ...
Support Center